Out of 61 people with HIV and fatty liver disease in the study, 39 were taking integrase inhibitors, and most of those (41% of all participants) were on dolutegravir.

Scientific Claim

Among 61 participants with HIV-associated non-alcoholic fatty liver disease in the study, 39 (64%) were receiving integrase inhibitor-containing regimens, with dolutegravir being the most common (41% of the total cohort).

Original Statement

“Amongst participants, 39 (64%) were on INSTI containing regimens, the most common of which was dolutegravir (41%).”

From study:1499. Tesamorelin Reduces Visceral Adipose Tissue and Liver Fat in INSTI-Treated Persons with HIV

Evidence Quality Assessment

Claim Status

appropriately stated

Study Design Support

Design supports claim

Appropriate Language Strength

association

Can only show association/correlation

Assessment Explanation

This is a factual description of study demographics, accurately stated without causal implications.

Evidence from Studies

Supporting (1)

1499. Tesamorelin Reduces Visceral Adipose Tissue and Liver Fat in INSTI-Treated Persons with HIV

Randomized Controlled Trial

Human

Contradicting (0)

No contradicting evidence found

Source Study

1499. Tesamorelin Reduces Visceral Adipose Tissue and Liver Fat in INSTI-Treated Persons with HIV

Score: 63

DOI: 10.1093/ofid/ofad500.1334

Similar Assertions

Out of 61 people with HIV and fatty liver in the study, 39 were on INSTI drugs, and most of those (41%) were taking dolutegravir.

95%

In the study, most people with HIV and fatty liver disease on INSTI drugs were taking dolutegravir, which made up 41% of those on INSTIs.

91%

Before starting treatment, people with HIV and fatty liver disease who were taking integrase inhibitors had similar body measurements as those not taking them.

83%

People with HIV and fatty liver disease who were on INSTI drugs had similar body measurements at the start of the study compared to those not on INSTIs.

81%

Researchers looked at data from a previous study where 61 people with HIV and fatty liver disease were given either tesamorelin or a placebo, then focused on those taking integrase inhibitor drugs.

80%